Diabetes is one the world's most widespread diseases, affecting over 327 million people and causing about 300,000 deaths annually. Despite great advances in prevention and therapy, existing treatments for this disorder have serious side effects. Plants used in traditional medicine represent a valuable source in the search for new medicinal compounds. Jacq. has been used for treating diabetes and, so far, no reports have been made on the antihyperglycemic activity of this plant. The present study on aimed to test the antihyperglycemic effect of repeated administrations of the crude and fractional methanolic extracts (CME and FME, respectively) on rats with hyperglycemia induced by streptozotocin. After 10 administrations (20 days), each extract had lowered blood glucose to a normal level. The extracts produced effects similar to metformin. Of the five compounds identified by chromatographic analysis of the extracts, epicatechin and chlorogenic acid demonstrated antihyperglycemic effect. The antioxidant activity of the extracts was evidenced by their IC values (51.7 and 50.7 g/mL, respectively). The LD≥2000 mg/Kg suggests low toxicity for both CME and FME. Thus, considering that the antihyperglycemic and antioxidant effects of metformin and extracts from were comparable, the latter may be efficacious for treating diabetes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129850PMC
http://dx.doi.org/10.1155/2018/7926452DOI Listing

Publication Analysis

Top Keywords

antihyperglycemic activity
8
treating diabetes
8
cme fme
8
effects metformin
8
antihyperglycemic antioxidant
8
extracts
6
antihyperglycemic
5
"diabetes metabolism
4
metabolism disorders
4
disorders medicinal
4

Similar Publications

Aim: Pancreatic β-cells are susceptible to inflammation, leading to decreased insulin production/secretion and cell death. Previously, we have identified a novel triceps-derived myokine, DECORIN, which plays a pivotal role in skeletal muscle-to-pancreas interorgan communication. However, whether DECORIN can directly impact β-cell function and susceptibility to inflammation remains unexplored.

View Article and Find Full Text PDF

Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.

BMJ

January 2025

Ministry of Education Key Laboratory of Metabolism and Molecular Medicine, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.

Objective: To assess the effect of dapagliflozin plus calorie restriction on remission of type 2 diabetes.

Design: Multicentre, double blind, randomised, placebo controlled trial.

Setting: 16 centres in mainland China from 12 June 2020 to 31 January 2023.

View Article and Find Full Text PDF

Macroalgae growing in the polar regions are exposed to extreme environment conditions and may induce differences in the structural and bioactive properties of their polysaccharides. Six brown macroalgae viz. kelp species - Saccharina latissima, Laminaria digitata, and Alaria esculenta; rockweed Fucus distichus; and filamentous macroalgae - Chorda filum and Chordaria flageliformis, from the Arctic were investigated for polysaccharides and their bioactivity.

View Article and Find Full Text PDF

Diabetes mellitus, characterized by high blood glucose due to inadequate insulin action, comprises two main types: type 1, an autoimmune disease, and type 2, marked by insulin resistance. This review provides a comprehensive overview of diabetes management and treatment advancements. Effective diabetes management includes maintaining blood glucose levels within normal ranges and monitoring HbA1c, a marker reflecting average glucose levels over the past few months.

View Article and Find Full Text PDF

Background: In May 2020, the US Food and Drug Administration (FDA) asked 5 pharmaceutical companies to voluntarily recall some formulations of metformin due to contamination. This observational study sought to provide insight changes in hemoglobin A (HbA) levels when veterans switched to alternative antihyperglycemic agents following the recall.

Methods: This study included veterans aged ≥ 18 years with type 2 diabetes who were receiving health care from Veterans Integrated Service Network 6 and had an active metformin sustained-action (SA) prescription as of June 1, 2020.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!